IL5 and COVID-19: Anti-interleukin-5 (anti-IL-5) and anti-immunoglobulin E (anti-IgE) agents have already demonstrated significant reductions in asthma exacerbations [61], while anti-C5a antibodies are being explored in the context of sepsis-related acute respiratory distress syndrome (ARDS) and COVID-19 [62,63].